Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
New England Journal of Medicine2018Vol. 379(1), pp. 11–21
Citations Over TimeTop 1% of 2018 papers
David Adams, Alejandra González‐Duarte, William O’Riordan, Chih‐Chao Yang, Mitsuharu Ueda, Arnt V. Kristen, Ivailo Tournev, Hartmut Schmidt, Teresa Coelho, John L. Berk, Kon-Ping Lin, Giuseppe Vita, Shahram Attarian, Violaine Planté‐Bordeneuve, Michelle M. Mezei, Josep M. Campistol, Juan Buades, Thomas H. Brannagan, Byoung J. Kim, Jeeyoung Oh, Yeşim Parman, Yoshiki Sekijima, Philip N. Hawkins, Scott D. Solomon, Michael Polydefkis, P. James B. Dyck, Pritesh J. Gandhi, Sunita Goyal, Jihong Chen, Andrew Strahs, Saraswathy V. Nochur, Marianne T. Sweetser, Pushkal Garg, Akshay Vaishnaw, Jared Gollob, Ole B. Suhr
Abstract
In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).
Related Papers
- → Spinal multifocal amyloidosis derived from wild-type transthyretin(2011)25 cited
- → Transthyretin amyloidosis: a little history of hereditary amyloidosis(2017)7 cited
- → New Medications in the Treatment of Hereditary Transthyretin Amyloidosis(2018)4 cited
- → Systemic transtiretin amyloidosis in the elderly patient with recurrent pleural effusions(2021)1 cited
- → Structurally abnormal transthyretin causing familial amyloidotic polyneuropathy in Sweden(1987)28 cited